$FNCH
Finch Therapeutics Group, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024096246 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.109M
YoY Change -31.18%
% of Gross Profit
Research & Development $0.00
YoY Change -100.0%
% of Gross Profit
Depreciation & Amortization $44.00K
YoY Change -22.81%
% of Gross Profit
Operating Expenses $6.109M
YoY Change -38.17%
Operating Profit -$6.109M
YoY Change -38.17%
Interest Expense $227.0K
YoY Change -45.95%
% of Operating Profit
Other Income/Expense, Net $1.275M
YoY Change -56.5%
Pretax Income -$4.834M
YoY Change -30.45%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$4.834M
YoY Change -30.45%
Net Earnings / Revenue
Basic Earnings Per Share -$3.01
Diluted Earnings Per Share -$3.01
COMMON SHARES
Basic Shares Outstanding 1.606M 1.606M
Diluted Shares Outstanding 1.606M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $16.04M
YoY Change -52.91%
Cash & Equivalents $16.04M
Short-Term Investments
Other Short-Term Assets $1.244M
YoY Change -49.18%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $17.28M
YoY Change -52.66%
LONG-TERM ASSETS
Property, Plant & Equipment $507.0K
YoY Change -30.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.349M
YoY Change
Total Long-Term Assets $28.30M
YoY Change -6.79%
TOTAL ASSETS
Total Short-Term Assets $17.28M
Total Long-Term Assets $28.30M
Total Assets $45.58M
YoY Change -31.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $29.00K
YoY Change -93.29%
Accrued Expenses $4.433M
YoY Change -51.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.462M
YoY Change -53.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $26.90M
YoY Change
Total Long-Term Liabilities $26.90M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.462M
Total Long-Term Liabilities $26.90M
Total Liabilities $31.36M
YoY Change -19.52%
SHAREHOLDERS EQUITY
Retained Earnings -$359.1M
YoY Change 4.11%
Common Stock $373.3M
YoY Change 0.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $14.22M
YoY Change
Total Liabilities & Shareholders Equity $45.58M
YoY Change -31.83%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$4.834M
YoY Change -30.45%
Depreciation, Depletion And Amortization $44.00K
YoY Change -22.81%
Cash From Operating Activities -$4.726M
YoY Change -48.39%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -4.726M
Cash From Investing Activities 0.000
Cash From Financing Activities 0.000
Net Change In Cash -4.726M
YoY Change -40.05%
FREE CASH FLOW
Cash From Operating Activities -$4.726M
Capital Expenditures $0.00
Free Cash Flow -$4.726M
YoY Change -48.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001733257
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40227
dei Entity Registrant Name
EntityRegistrantName
FINCH THERAPEUTICS GROUP, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-3433558
dei Entity Address Address Line1
EntityAddressAddressLine1
75 State Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02109
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
229-6499
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
FNCH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1605763
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16035000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25124000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1244000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
723000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
17279000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
25847000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
507000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
594000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25441000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26584000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2349000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2348000
CY2024Q2 us-gaap Assets
Assets
45576000
CY2023Q4 us-gaap Assets
Assets
55373000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
29000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
141000
CY2024Q2 fnch Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2339000
CY2023Q4 fnch Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2220000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2094000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1723000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4462000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4084000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26895000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28403000
CY2024Q2 us-gaap Liabilities
Liabilities
31357000
CY2023Q4 us-gaap Liabilities
Liabilities
32487000
CY2024Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2023Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2024Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2023Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2024Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1605763
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1605763
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1605763
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1605763
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
2000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
373322000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
373279000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-359105000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-350395000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
14219000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
22886000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
45576000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55373000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
107000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
107000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
203000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7199000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6109000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8877000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11273000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18494000
CY2024Q2 fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
0
CY2023Q2 fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
0
fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
0
fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
32900000
CY2024Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
13141000
CY2024Q2 us-gaap Restructuring Charges
RestructuringCharges
0
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
801000
us-gaap Restructuring Charges
RestructuringCharges
34000
us-gaap Restructuring Charges
RestructuringCharges
4037000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
6109000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
9881000
us-gaap Operating Expenses
OperatingExpenses
11307000
us-gaap Operating Expenses
OperatingExpenses
75771000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6109000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9881000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11307000
us-gaap Operating Income Loss
OperatingIncomeLoss
-75664000
CY2024Q2 us-gaap Investment Income Net
InvestmentIncomeNet
227000
CY2023Q2 us-gaap Investment Income Net
InvestmentIncomeNet
420000
us-gaap Investment Income Net
InvestmentIncomeNet
507000
us-gaap Investment Income Net
InvestmentIncomeNet
845000
CY2024Q2 fnch Gain Loss On Lease Termination
GainLossOnLeaseTermination
0
CY2023Q2 fnch Gain Loss On Lease Termination
GainLossOnLeaseTermination
752000
fnch Gain Loss On Lease Termination
GainLossOnLeaseTermination
0
CY2023Q2 fnch Gain Loss On Lease Termination
GainLossOnLeaseTermination
752000
CY2024Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1366000
CY2024Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
CY2023Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
754000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
617000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1048000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1005000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2090000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2058000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1275000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2931000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2597000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2906000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4834000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6950000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8710000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-72758000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3461000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-4834000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6950000
us-gaap Net Income Loss
NetIncomeLoss
-8710000
us-gaap Net Income Loss
NetIncomeLoss
-69297000
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.01
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.01
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.33
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.33
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-43.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-43.21
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1605763
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1605763
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1604795
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1604795
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1605763
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1605763
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1603811
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1603811
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
95711000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1180000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-62347000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
34544000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
300000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6950000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
27894000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
22886000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3876000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
19038000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-4834000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
14219000
us-gaap Profit Loss
ProfitLoss
-8710000
us-gaap Profit Loss
ProfitLoss
-69297000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
87000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1424000
us-gaap Share Based Compensation
ShareBasedCompensation
43000
us-gaap Share Based Compensation
ShareBasedCompensation
1480000
fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
0
fnch Impairment Of In Process Research And Development
ImpairmentOfInProcessResearchAndDevelopment
32900000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
13141000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
0
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
752000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1366000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
617000
fnch Non Cash Interest Expense
NonCashInterestExpense
1143000
fnch Non Cash Interest Expense
NonCashInterestExpense
1939000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-3461000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-144000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
521000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-921000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-4033000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-112000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-664000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
119000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2676000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-50000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1137000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2369000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9088000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22538000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1270000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1256000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
15000000
fnch Payment Of Loan Prepayment And Termination Fee
PaymentOfLoanPrepaymentAndTerminationFee
0
fnch Payment Of Loan Prepayment And Termination Fee
PaymentOfLoanPrepaymentAndTerminationFee
1155000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-16155000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9088000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-37437000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27472000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
73805000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18384000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36369000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16000000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16035000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25124000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2349000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2348000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18384000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27472000
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
917000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
427000
CY2024Q2 fnch Other Prepaid Expenses And Other Current Assets
OtherPrepaidExpensesAndOtherCurrentAssets
327000
CY2023Q4 fnch Other Prepaid Expenses And Other Current Assets
OtherPrepaidExpensesAndOtherCurrentAssets
296000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1244000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
723000
us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
1400000
CY2023Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
13100000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2228000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1301000
CY2024Q2 fnch Refundable Tax Credited
RefundableTaxCredited
0
CY2023Q4 fnch Refundable Tax Credited
RefundableTaxCredited
418000
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
260000
CY2024Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
18000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
125000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
93000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
116000
CY2024Q2 fnch Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2339000
CY2023Q4 fnch Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2220000
CY2024Q2 fnch Transfers Between Fair Value Levels
TransfersBetweenFairValueLevels
0
CY2023Q4 fnch Transfers Between Fair Value Levels
TransfersBetweenFairValueLevels
0
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25441000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26584000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2094000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1723000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26895000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28403000
CY2024Q2 fnch Lease Liabilities
LeaseLiabilities
28989000
CY2023Q4 fnch Lease Liabilities
LeaseLiabilities
30126000
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1202000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1678000
us-gaap Operating Lease Cost
OperatingLeaseCost
2404000
us-gaap Operating Lease Cost
OperatingLeaseCost
3405000
CY2024Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
4000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
us-gaap Short Term Lease Cost
ShortTermLeaseCost
17000
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
578000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
87000
us-gaap Variable Lease Cost
VariableLeaseCost
999000
us-gaap Variable Lease Cost
VariableLeaseCost
532000
CY2024Q2 us-gaap Sublease Income
SubleaseIncome
1048000
CY2023Q2 us-gaap Sublease Income
SubleaseIncome
959000
us-gaap Sublease Income
SubleaseIncome
2090000
us-gaap Sublease Income
SubleaseIncome
1919000
CY2024Q2 us-gaap Lease Cost
LeaseCost
732000
CY2023Q2 us-gaap Lease Cost
LeaseCost
810000
us-gaap Lease Cost
LeaseCost
1313000
us-gaap Lease Cost
LeaseCost
2035000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y6M
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.085
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.085
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1137000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2369000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1998000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4931000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5071000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5215000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5364000
CY2024Q2 fnch Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
17026000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
39605000
CY2024Q2 fnch Interest Portion Of Operating Leases Future Minimum Payments Due
InterestPortionOfOperatingLeasesFutureMinimumPaymentsDue
-10616000
CY2024Q2 fnch Present Value Of Future Minimum Lease Payments
PresentValueOfFutureMinimumLeasePayments
28989000
CY2024Q2 fnch Operating Subleases Undiscounted Cash Flows Received Next Twelve Months
OperatingSubleasesUndiscountedCashFlowsReceivedNextTwelveMonths
2127000
CY2024Q2 fnch Operating Subleases Undiscounted Cash Flows Received Year Two
OperatingSubleasesUndiscountedCashFlowsReceivedYearTwo
3135000
CY2024Q2 fnch Operating Subleases Undiscounted Cash Flows Received
OperatingSubleasesUndiscountedCashFlowsReceived
5262000
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
800000
us-gaap Restructuring Charges
RestructuringCharges
4000000
us-gaap Restructuring Costs
RestructuringCosts
3900000
CY2024Q2 fnch Commitments And Contingencies Due In Next Twelve Months
CommitmentsAndContingenciesDueInNextTwelveMonths
20000
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holder to one vote
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
300000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
43000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1480000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4834000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4834000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6950000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6950000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8710000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-8710000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-69297000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-69297000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1605763
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1605763
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1604795
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1604795
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1605763
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1605763
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1603811
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1603811
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.01
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.01
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.33
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.42
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-43.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-43.21

Files In Submission

Name View Source Status
0000950170-24-096246-index-headers.html Edgar Link pending
0000950170-24-096246-index.html Edgar Link pending
0000950170-24-096246.txt Edgar Link pending
0000950170-24-096246-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
fnch-20240630.htm Edgar Link pending
fnch-20240630.xsd Edgar Link pending
fnch-ex31_1.htm Edgar Link pending
fnch-20240630_htm.xml Edgar Link completed
fnch-ex31_2.htm Edgar Link pending
fnch-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable